ZBD(SH:603567)2016-04-26 16:00Financial Performance - Operating revenue for the period reached CNY 409,602,062.43, representing a significant increase of 96.22% year-on-year[5] - Net profit attributable to shareholders of the listed company was CNY 67,048,960.12, up 142.92% from the same period last year[5] - Basic earnings per share increased by 105.87% to CNY 0.1579[5] - The diluted earnings per share rose by 117.14% to CNY 0.1520[5] - Total revenue for the reporting period reached RMB 409,602,062.43, representing a 96.22% increase compared to RMB 208,745,056.20 in the same period last year[12] - The net profit for Q1 2016 reached CNY 79,161,987.45, representing a growth of 29.2% from CNY 61,279,496.79 in Q1 2015[32] - The total profit for Q1 2016 was CNY 93,111,850.10, an increase of 28.4% from CNY 72,526,959.04 in Q1 2015[32] - The company's total comprehensive income for Q1 2016 was CNY 79,161,987.45, compared to CNY 61,279,496.79 in the previous year, marking a growth of 29.2%[33] Cash Flow - The net cash flow from operating activities was negative at CNY -284,338,567.63, a decline of 147.49% compared to the previous year[5] - Net cash flow from operating activities was -75,203,338.85 RMB, a significant decrease compared to 159,040,164.87 RMB in the previous period, indicating a decline of approximately 147.3%[37] - The cash flow from financing activities was -9,863,388.89 RMB, a decrease from -212,058,052.80 RMB in the previous period, indicating an improvement of approximately 95.3%[38] - The company reported cash outflows related to operating activities amounting to 192,795,923.67 RMB, which is a 102.5% increase compared to 95,414,910.20 RMB in the previous period[37] - The cash inflow from sales of goods and services was 113,851,511.51 RMB, which is a 112.6% increase compared to 53,450,798.00 RMB in the previous period[37] - The company incurred cash payments for taxes amounting to 58,508,611.91 RMB, which is a significant increase from 23,374,810.80 RMB in the previous period, reflecting a rise of approximately 150.5%[37] - The cash inflow from investment activities totaled 223,000,000.00 RMB, while cash outflow was 145,303,120.84 RMB, resulting in a net cash flow of 77,696,879.16 RMB, contrasting with a negative cash flow of -2,063,636.41 RMB in the prior period[38] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,918,850,117.08, a decrease of 0.52% compared to the end of the previous year[5] - The company's cash and cash equivalents decreased from CNY 1,701,404,562.78 at the beginning of the year to CNY 1,388,938,186.32 by the end of the reporting period, representing a decline of approximately 18.4%[21] - Accounts receivable increased from CNY 237,391,878.25 to CNY 293,339,663.30, showing an increase of about 23.5%[21] - Inventory rose from CNY 1,378,434,517.46 to CNY 1,544,291,319.02, indicating an increase of approximately 12.0%[21] - Total current assets slightly decreased from CNY 4,238,941,383.40 to CNY 4,197,138,040.75, a reduction of about 1.0%[21] - Total liabilities decreased to CNY 1,233,349,507.64 from CNY 1,264,085,862.97 at the beginning of the year[27] Shareholder Information - The number of shareholders at the end of the reporting period was 31,889[10] - The largest shareholder, Hulin Chuangda Investment Co., Ltd., held 67.83% of the shares, with 288,000,000 shares pledged[10] - The company committed to not transferring more than 25% of its total shareholding annually after the lock-up period ends[16] - The controlling shareholder is allowed to increase their stake by up to 2% of the total issued shares within six months if the stock price remains below the net asset value for 20 consecutive trading days[18] - The company has committed to disclose any failure to fulfill obligations related to share repurchase or stake increase within two trading days, along with an apology to shareholders[19] Commitments and Guarantees - As of the date of the commitment letter, the company has not engaged in any competing business with Zhenbao Island Pharmaceutical[16] - The company guarantees that it will not provide any financial, business, or technical assistance to competitors of Zhenbao Island Pharmaceutical[16] - The commitment is effective until the shareholder no longer holds more than 5% of Zhenbao Island Pharmaceutical's shares[17] - The company will compensate Zhenbao Island Pharmaceutical for any losses incurred due to violations of the commitments within 60 days of loss confirmation[17] - The company will repurchase shares if the prospectus contains false statements or omissions that materially affect the judgment of compliance with legal regulations[17] - The repurchase price will be consistent with the market price at the time of repurchase, adjusted for any stock splits or capital increases[17] - The company will compensate investors for losses incurred due to false statements in the prospectus, including investment losses, commissions, and stamp duties[17] - The company has prioritized the right to acquire new technologies and products developed by the shareholders that may compete with its business[16] - The company will take necessary actions to avoid direct or indirect competition with Zhenbao Island Pharmaceutical's business[16]